There is also evidence that the intranasal administration of AVP reduces state anxiety in men regardless of dose size; however, in people (both genders) carrying a “risk” allele in the RS3 promoter of the AVPR1A (arginine vasopressin receptor 1A) gene, this effect is visible also after administering lower doses [152]. This evidence concerns the gene AVPR1A and Anxiety.